Personalized Microbiome Modulation to Improve Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Multi-Omics and Interventional Approach
Open Access
- 30 April 2025
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 13 (5) , 1047
Abstract
Inflammatory bowel disease (IBD) is a complex disorder influenced by genetic, environmental, and microbial factors, with emerging evidence highlighting the gut microbiome’s role in disease pathogenesis. This study investigates the impact of microbiome-targeted interventions in pediatric IBD by integrating multi-omics analysis, including metagenomics, metabolomics, transcriptomics, and clinical biomarkers, to identify microbial dysbiosis patterns and potential therapeutic targets. A cohort of pediatric IBD patients underwent a personalized intervention involving dietary modifications, probiotic supplementation, and selective antibiotic therapy. Microbiome composition, inflammatory markers (fecal calprotectin, CRP), and disease activity scores (PCDAI/PUCAI) were assessed before and after treatment. At the 3-month follow-up, patients showed significant clinical improvement, with reduced stool frequency (p = 0.004) and improved stool consistency (p < 0.001). Symptoms such as bloating and abdominal pain decreased, while energy levels increased (p < 0.001). Dietary changes included higher fruit, meat, and dairy intake, and lower fast-food and sweets consumption (p < 0.001). Physician assessments classified 90% as “improved”, reinforcing the effectiveness of personalized microbiome interventions. Microbiome-targeted interventions (diet, probiotics, and selective antibiotics) improved pediatric IBD outcomes by reducing pathogenic bacteria and increasing short-chain fatty acid (SCFA)-producing species, lowering inflammation and symptoms. Early-life factors (cesarean birth, and formula feeding) influence IBD risk. Personalized diets enhanced microbial balance. Integrating multi-omics supports precision medicine, offering microbiome-based biomarkers and reducing immunosuppressive reliance.Keywords
Funding Information
- “Victor Babes” University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania
This publication has 42 references indexed in Scilit:
- Integrating multi-omics to unravel host-microbiome interactions in inflammatory bowel diseaseCell Reports Medicine, 2024
- Persistent dysbiosis of duodenal microbiota in patients with controlled pediatric Crohn’s disease after resolution of inflammationScientific Reports, 2024
- Tackling the threat of antimicrobial resistance in neonates and children: outcomes from the first WHO-convened Paediatric Drug Optimisation exercise for antibioticsThe Lancet Child & Adolescent Health, 2024
- Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic ReviewGastroenterology, 2022
- Early‐Life Gut Microbiome—The Importance of Maternal and Infant Factors in Its EstablishmentNutrition in Clinical Practice, 2020
- Multi-omics of the gut microbial ecosystem in inflammatory bowel diseasesNature, 2019
- Dynamics of the human gut microbiome in inflammatory bowel diseaseNature Microbiology, 2017
- Association of Cesarean Delivery and Formula Supplementation With the Intestinal Microbiome of 6-Week-Old InfantsJAMA Pediatrics, 2016
- The Microbiome in Inflammatory Bowel Disease: Current Status and the Future AheadGastroenterology, 2014
- The Treatment-Naive Microbiome in New-Onset Crohn’s DiseaseCell Host & Microbe, 2014